FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306320232> ?p ?o ?g. }

• W4306320232 abstract "Abstract Background Bioprosthetic valve thrombosis is currently a well-recognized cause of bioprosthetic valve dysfunction. It was found to be associated with accelerated degeneration of the bioprosthesis with higher rates of valve re-replacement, even after treatment with anticoagulation. We hypothesized that the use of warfarin for three months after transcatheter aortic valve replacement (TAVR) protects against accelerated valve degeneration and is therefore associated with better outcomes compared to dual antiplatelet therapy (DAPT). Methods Consecutive adult patients who underwent TAVR in our clinic between 2012 and 2019 were identified retrospectively. Patients with atrial fibrillation were excluded. Subsequently, patients who received DAPT were propensity matched to up to 2 patients who received three months of warfarin as part of their anti-thrombotic regimen. Matching was performed for variables that were significantly different at baseline between the two groups and included diabetes mellitus, prior myocardial infarctions, chronic lung disease, peripheral arterial disease, hemoglobin at time of TAVR, kidney function [creatinine&gt;2], use of angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers, beta blockers, the Society of Thoracic Surgeons (STS) score [STS ≥8, STS 4–8, STS&lt;4], and valve size. The two groups were then compared for outcomes of ischemic stroke, death, valve re-replacement/intervention, the composite endpoint of the aforementioned three outcomes, as well as the three-month outcome of hemorrhagic strokes. Kaplan Meier was used for outcome analysis, and discharge date was considered time zero. Patients who had their anti-thrombotic therapy interrupted were censored at that time point. Results A total of 1,373 patients who underwent TAVR were identified. Of these, 576 patients with atrial fibrillation were excluded. Baseline characteristics were compared between 633 patients who received three months of warfarin and 164 patients who received DAPT after TAVR. After matching the two groups, 435 patients were included in the final analysis [warfarin in 281, DAPT in 154; median time to last follow up 2.61 years], Table 1. There was no difference in matched (Figure 1) or unmatched analysis (not shown) in outcomes of ischemic stroke, death, valve re-replacement/intervention, their composite endpoint, or hemorrhagic strokes (p&gt;0.05 for all). Conclusion Antithrombotic regimen including three months of warfarin after TAVR was not associated with better outcomes of ischemic strokes, deaths, and valve re-replacement/intervention or with increased risk of hemorrhagic strokes compared to DAPT. Funding Acknowledgement Type of funding sources: None." @default.
• W4306320232 created "2022-10-16" @default.
• W4306320232 creator A5003406416 @default.
• W4306320232 creator A5004388110 @default.
• W4306320232 creator A5013317227 @default.
• W4306320232 creator A5029988957 @default.
• W4306320232 creator A5038064913 @default.
• W4306320232 creator A5039047362 @default.
• W4306320232 creator A5044601513 @default.
• W4306320232 creator A5077475480 @default.
• W4306320232 creator A5086970664 @default.
• W4306320232 creator A5089152920 @default.
• W4306320232 date "2022-10-01" @default.
• W4306320232 modified "2023-10-18" @default.
• W4306320232 title "The use of warfarin as part of antithrombotic strategy after transcutaneous aortic valve replacement is not associated with better medium-term outcomes" @default.
• W4306320232 doi "https://doi.org/10.1093/eurheartj/ehac544.2705" @default.
• W4306320232 hasPublicationYear "2022" @default.
• W4306320232 type Work @default.
• W4306320232 citedByCount "0" @default.
• W4306320232 crossrefType "journal-article" @default.
• W4306320232 hasAuthorship W4306320232A5003406416 @default.
• W4306320232 hasAuthorship W4306320232A5004388110 @default.
• W4306320232 hasAuthorship W4306320232A5013317227 @default.
• W4306320232 hasAuthorship W4306320232A5029988957 @default.
• W4306320232 hasAuthorship W4306320232A5038064913 @default.
• W4306320232 hasAuthorship W4306320232A5039047362 @default.
• W4306320232 hasAuthorship W4306320232A5044601513 @default.
• W4306320232 hasAuthorship W4306320232A5077475480 @default.
• W4306320232 hasAuthorship W4306320232A5086970664 @default.
• W4306320232 hasAuthorship W4306320232A5089152920 @default.
• W4306320232 hasBestOaLocation W43063202321 @default.
• W4306320232 hasConcept C126322002 @default.
• W4306320232 hasConcept C127413603 @default.
• W4306320232 hasConcept C141071460 @default.
• W4306320232 hasConcept C164705383 @default.
• W4306320232 hasConcept C2776301958 @default.
• W4306320232 hasConcept C2776570981 @default.
• W4306320232 hasConcept C2778213512 @default.
• W4306320232 hasConcept C2779161974 @default.
• W4306320232 hasConcept C2780007028 @default.
• W4306320232 hasConcept C2780026749 @default.
• W4306320232 hasConcept C2780645631 @default.
• W4306320232 hasConcept C71924100 @default.
• W4306320232 hasConcept C78519656 @default.
• W4306320232 hasConceptScore W4306320232C126322002 @default.
• W4306320232 hasConceptScore W4306320232C127413603 @default.
• W4306320232 hasConceptScore W4306320232C141071460 @default.
• W4306320232 hasConceptScore W4306320232C164705383 @default.
• W4306320232 hasConceptScore W4306320232C2776301958 @default.
• W4306320232 hasConceptScore W4306320232C2776570981 @default.
• W4306320232 hasConceptScore W4306320232C2778213512 @default.
• W4306320232 hasConceptScore W4306320232C2779161974 @default.
• W4306320232 hasConceptScore W4306320232C2780007028 @default.
• W4306320232 hasConceptScore W4306320232C2780026749 @default.
• W4306320232 hasConceptScore W4306320232C2780645631 @default.
• W4306320232 hasConceptScore W4306320232C71924100 @default.
• W4306320232 hasConceptScore W4306320232C78519656 @default.
• W4306320232 hasIssue "Supplement_2" @default.
• W4306320232 hasLocation W43063202321 @default.
• W4306320232 hasOpenAccess W4306320232 @default.
• W4306320232 hasPrimaryLocation W43063202321 @default.
• W4306320232 hasRelatedWork W1983415041 @default.
• W4306320232 hasRelatedWork W1998461468 @default.
• W4306320232 hasRelatedWork W2039531178 @default.
• W4306320232 hasRelatedWork W2076292091 @default.
• W4306320232 hasRelatedWork W2140623030 @default.
• W4306320232 hasRelatedWork W2157689025 @default.
• W4306320232 hasRelatedWork W2172069617 @default.
• W4306320232 hasRelatedWork W2415605004 @default.
• W4306320232 hasRelatedWork W2513466485 @default.
• W4306320232 hasRelatedWork W3193900294 @default.
• W4306320232 hasVolume "43" @default.
• W4306320232 isParatext "false" @default.
• W4306320232 isRetracted "false" @default.
• W4306320232 workType "article" @default.